HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

J 113397

Subscribe to New Research on J 113397

an opioid receptor-like 1 (ORL1), orphanin FQ, and nociceptin receptor antagonist; structure in first source

Also Known As:

1-(1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl)-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one; CompB; J-113397

Networked: 10 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Piperidines: 12
    - J 113397: 10
- 2-Ring Heterocyclic Compounds
  - Benzimidazoles: 111
    - J 113397: 10

Experts

1.	Trapella, Claudio: 2 articles (06/2008 - 02/2007)
2.	Viaro, Riccardo: 2 articles (06/2008 - 02/2007)
3.	Morari, Michele: 2 articles (06/2008 - 02/2007)
4.	Marti, Matteo: 2 articles (06/2008 - 02/2007)
5.	Iwasawa, Y: 2 articles (10/2000 - 08/2000)
6.	Cremeans, Colette M: 1 article (10/2012)
7.	Ko, Mei-Chuan: 1 article (10/2012)
8.	Kyle, Donald J: 1 article (10/2012)
9.	Gruley, Erin: 1 article (10/2012)
10.	Scoto, Giovanna M: 1 article (01/2012)

Related Diseases

1.	Parkinsonian Disorders (Parkinsonism) 06/01/2008 - "In naïve nonhuman primates, J-113397, ineffective up to 1 mg/kg, produced inconsistent motor improvements at 3 mg/kg. Conversely, in parkinsonian primates J-113397 (0.01 mg/kg) reversed parkinsonism, being most effective against hypokinesia. " 02/07/2007 - "The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway."
2.	Hypokinesia (Bradykinesia) 06/01/2008 - "In naïve nonhuman primates, J-113397, ineffective up to 1 mg/kg, produced inconsistent motor improvements at 3 mg/kg. Conversely, in parkinsonian primates J-113397 (0.01 mg/kg) reversed parkinsonism, being most effective against hypokinesia. " 06/01/2008 - "Likewise, in MPTP-treated mice, J-113397 reversed motor deficit at 0.01 mg/kg but worsened hypokinesia at higher doses (1 mg/kg). "
3.	Seizures (Seizure) 11/15/2002 - "Mice treated with the NOP receptor antagonist J-113397 displayed reduced susceptibility to kainate-induced seizures (i.e., significant reduction of behavioral seizure scores). "
4.	Prion Diseases (Transmissible Spongiform Encephalopathies) 02/01/2009 - "Nevertheless, because compB studies suggest that amyloidophilic compounds are also therapeutic candidates for Alzheimer's disease, amyloidophilic compounds might be attractive as drug candidates for various conformational diseases and hasten development of therapeutic drugs for prion diseases."
5.	Alzheimer Disease (Alzheimer's Disease) 02/01/2009 - "Nevertheless, because compB studies suggest that amyloidophilic compounds are also therapeutic candidates for Alzheimer's disease, amyloidophilic compounds might be attractive as drug candidates for various conformational diseases and hasten development of therapeutic drugs for prion diseases."

Related Drugs and Biologics

1.	Kainic Acid (Kainate)
2.	nociceptin
3.	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
4.	Levodopa (L Dopa)
5.	Sodium
6.	Naltrexone (ReVia)
7.	Naloxone (Narcan)
8.	Buprenorphine (Subutex)
9.	Adenylate Cyclase (Adenylyl Cyclase)
10.	8- (bis(2- methylphenyl)methyl)- 3- phenyl- 8- azabicyclo(3.2.1)octan- 3- ol

Related Therapies and Procedures

1.	Injections
2.	Analgesia